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Abstract Recently, systemic administration of a human
monoclonal antibody directed against cytotoxic T
lymphocyte-associated antigen 4 (CTLA-4) expressed on cir-
culating T cells in patients with chronic lymphocytic leukae-
mia (CLL) has been considered. Also, CLL cells have been
shown to express CTLA-4, increased levels of which in the
leukaemic compartment are a predictor of good clinical out-
come. Since both CLL and Treg microenvironment cells can
be targeted by the CTLA-4 blocking antibody in this immu-
notherapy approach, the investigation of the functional effect
of CTLA-4 blockade on CLL cells might be of potential clin-
ical relevance. The main aim of this study was to examine the
effect of CTLA-4 blockade on proliferation activity and apo-
ptosis of CLL cells in patients with low and high CTLA-4
expression. We found that in the high CTLA-4-expressing
CLL group, CTLA-4 blockade on the CLL cell surface result-
ed in a significant increase in the median percentages of Ki67+
cells and a tendency to decrease in the proportion of apoptotic
cells. In contrast, in the low CTLA-4 expressors, CTLA-4
blockade did not affect the proliferation activity or the fre-
quency of apoptosis. This study reports for the first time the
different effect of CTLA-4 blockade on CLL cells in CLL
patients depending on the levels of CTLA-4 expression.
CTLA-4 blockade seems to induce pro-survival signals in
leukaemic cells from CLL patients exhibiting high CTLA-4
expression, suggesting that an immunotherapy approach
based on the systemic use of monoclonal anti-CTLA-4 anti-
bodies could be an unfavourable strategy for some CLL
patients.
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Introduction
Chronic lymphocytic leukaemia (CLL) is the most frequent
type of leukaemia recognised in North America, Europe and
Australasia, accounting for about one third of all cases of adult
leukaemia [1–3]. It is a disease of senior age, since the median
age at diagnosis is close to 70 years [2]. The diagnosis of CLL
is based on the identification of a monoclonal lymphocytosis
of morphologically mature CD19+CD5+ cells, which spread
to the peripheral blood, bonemarrow and secondary lymphoid
organs such as lymph nodes [2–4]. With progression of the
disease, lymphadenopathy, splenomegaly, hepatomegaly,
anaemia and thrombocytopenia can occur [2, 3]. Recent stud-
ies indicate that the progression and evolution of CLL can be
associated with increased proliferation of CLL cells in prolif-
eration centres (PCs) of lymph nodes and bone marrow
resulting from the interaction with the microenvironment
[5–9].
CLL patients display significant clinical heterogeneity [10,
11]. In some patients, the disease remains stable for many
years or develops very slowly [10, 11]. These patients live
for prolonged periods without any therapy or may never need
treatment in their lifetimes. In others, the disease progresses
quickly toward more advanced stages [10, 11]. These patients
require early therapy and die relatively rapidly despite
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aggressive treatment. Due to the variable clinical presentation
and evolution of CLL, it is important to identify prognostic
factors which will allow identification of CLL patients with
low and high risk of disease progression.
A protein recently considered as a prognostic factor in CLL
is cytotoxic T lymphocyte-associated antigen 4 (CTLA-4). It
has been reported that CTLA-4 acts as a negative regulator of
T cell activation and its engagement results in suppression of
cell proliferation and cytokine production [12, 13], whereas in
Treg cells, CTLA-4 is responsible for the suppressor function
of these cells [14]. The increased expression of the CTLA-4
molecule found in the T cell compartment in CLL patients
seems to be an unfavourable factor, because it specifically
inhibits anti-tumour immunity in these patients [15–17].
Therefore, monoclonal antibodies blocking CTLA-4 on the
surface of T cells including Tregs from CLL patients can aug-
ment anti-tumour immunity, and CTLA-4 blockade may rep-
resent a therapeutic opportunity to enhance the immune re-
sponses against autologous leukaemia cells [17]. In fact, pre-
vious studies have shown that CTLA-4 blockade enhanced
effector T cell function in CLL patients [17]. However, the
administration of CTLA-4 blocking antibody in CLL might
be complicated by the fact that the CTLA-4 molecule was
found to be also expressed on B lymphocytes including
leukaemic cells [18–21]. The CTLA-4 molecule is
overexpressed in peripheral blood CLL cells compared to nor-
mal B lymphocytes from healthy individuals, but the level of
its expression is very variable among CLL patients [18, 20]. It
has been found that the level of expression of the CTLA-4
gene in CLL cells is a reliable indicator predicting survival
and treatment requirements for CLL patients, since its higher
activity in these cells is associated with good clinical outcome,
and its lower expression is correlated with a significantly short
time to treatment and poor prognosis [19]. In addition, a poly-
morphism of the CTLA-4 gene may confer susceptibility to
CLL [22]. It was found that the presence of the T allele in the
polymorphic site -319C>T of the CTLA-4 gene increased the
risk of CLL and, in addition, was correlated with disease pro-
gression [22]. Actually, an association between expression of
the CTLA-4 molecule in CLL cells and the clinical parameters
has been demonstrated [18]. Higher expression of the CTLA-
4 molecule in CLL cells is associated with lower Rai stages
and lower leukocyte and lymphocyte count [18]. Our and
others’ research indicates that CTLA-4 might regulate G1
phase progression [18, 20] and inhibit the proliferation and
survival of leukaemic cells [21]. Based on all these findings,
systemic administration of a CTLA-4 blocking antibody
would affect not only T cell, but also CLL cell biology
[18–21].
As we recently reported variability of CTLA-4 expression
and its functional relevance in the CLL compartment [19–21],
we decided to investigate whether CLL patients differ in the
pattern of CLL cell responses to CTLA-4 blockade. The main
aim of this study was to investigate the proliferation activity
and apoptosis of CLL cells after blockade of the CTLA-4
molecule on the surface of leukaemic cells. A control stimu-
lating culture without CTLA-4 blockade was simultaneously
performed. All mentioned experiments were also performed
in normal B lymphocytes isolated from peripheral blood of
healthy individuals. An assessment of the effect of CTLA-4
blockade on proliferation and apoptosis of CLL cells may
contribute to determining whether systemic administration of
monoclonal anti-CTLA-4 antibodies is a favourable and safe
therapeutic strategy for all CLL patients. As some phase I/II
clinical trials using systemic administration of CTLA-4 block-
ade in haematologic malignancies, including CLL, showed
durable clinical responses in a relatively low proportion of
patients [23], we hope that the results of our in vitro blocking
experiments on CLL cells may provide new insights into the
safety and efficacy of this potential therapeutic approach in
CLL. To the best of our knowledge, such experiments carried
out on CLL cells are lacking so far.
Materials and methods
Patients and healthy donors
The study design was approved by the local Bioethical Com-
mittee at the Medical University ofWroclaw, Poland, and is in
accordance with the Helsinki Declaration of 1975. All partic-
ipants gave written informed consent after the purpose of the
study was explained to them. Thirty-eight previously untreat-
ed CLL patients of the Clinic of Haematology, Blood Neo-
plasms, and Bone Marrow Transplantation, WroclawMedical
University, Poland, were enrolled in this study. In each of
them, the diagnosis was established according to generally
accepted criteria including the absolute peripheral blood lym-
phocytosis ≥5×109/L and the co-expression of CD5, CD19
and CD23 antigens on malignant cells. The disease stages
were determined according to the Rai classification. Clinical
and laboratory features are presented in Table 1.
Leukocyte-enriched fractions of peripheral blood donated
by 15 healthy volunteers matched for age and sex with the
CLL patients were purchased from the Regional Centre of
Blood Donation and Treatment in Wroclaw, Poland.
Cell isolation and separation procedures
Peripheral blood mononuclear cells (PBMCs) were separated
from heparinised freshly drawn peripheral venous blood of
CLL patients and healthy controls by buoyant density gradient
centrifugation on Lymphoflot (Bio-Rad Medical Diagnostics
GmbH, Dreieich, Germany) and washed three times in
phosphate-buffered saline (PBS) (without Ca2+ and Mg2+).
The PBMCs were suspended in 95 % foetal calf serum
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(CytoGen GmbH, Sinn, Germany) containing 5 % DMSO
(Sigma-Aldrich, St. Gallen, Switzerland) and stored in liquid
nitrogen until used.
CLL cells were isolated from PBMCs by negative selection
using EasySep Human B Cell Enrichment Kit without CD43
Depletion (STEMCELL Technologies Inc, Vancouver, Cana-
da) according to the manufacturer’s instructions. Following
this separation procedure, more than 98 % of the resulting cell
population was CD19+CD5+ as assessed by flow cytometry
using anti-CD19 and anti-CD5 monoclonal antibodies
(mAbs) (Becton Dickinson, BD Biosciences, San Diego,
USA). Normal B cells from healthy individuals were isolated
from PBMCs by negative selection using the EasySep Human
B Cell Enrichment Kit (STEMCELL Technologies Inc, Van-
couver, Canada) according to the manufacturer’s instructions,
achieving above 98 % purity as assessed by flow cytometry
using anti-CD19 mAbs.
Culture conditions
Purified normal CD19+ lymphocytes or CLL cells were
suspended at 1×106 cells/ml in RPMI-1640 medium (Gibco,
Paisley, UK), supplemented with 10 % foetal calf serum
(CytoGen GmbH, Sinn, Germany), 2 mmol/l L-glutamine
and 50 μg/ml gentamycin (KRKA-Poland, Warsaw, Poland),
and cultured using 24-well U-bottom culture plates (Nunc
GmbH & Co. KG, Langenselbold, Germany) at 37 °C in a
5 % CO2 humidified atmosphere for 24 and 72 h either in
medium alone or together with 1 μM DSP30 (5 ′-
TCGTCGCTGTCTCCGCTTCTTCTTGCC-3 ′) (TIB
MOLBIOL, Berlin, Germany) [24] and 100 U/ml rIL-2
(Eurocetus, Amsterdam, The Netherlands) [25]. For the
blocking experiment, purified CLL cells and normal CD19+
lymphocytes were cultured with 1 μM DSP30 and 100 U/ml
IL-2 with the blocking anti-CTLA-4 mAbs (50 μg/ml) (BD
Pharmingen, BD Biosciences, San Diego, USA) [26] or con-
trol IgG2 (50 μg/ml) (BD Pharmingen, BD Biosciences, San
Diego, USA).
Immunostaining of CTLA-4, Ki67 protein and flow
cytometric analysis
The expression of these molecules was studied in purified
CLL cells and normal CD19+ lymphocytes before and after
24- and 72-h culture by a single immunostaining method.
Briefly, for detection of surface expression of the
CTLA-4 molecule, the cells were washed twice in PBS
(without Ca2+ and Mg2+), divided into tubes at a concen-
tration of 5×105 cells per tube and incubated with anti-
CTLA-4 (CD152)/retinal pigment epithelium (RPE)
mAbs (BD Pharmingen, BD Biosciences, San Diego,
USA) for 30 min at 4 °C in the dark. Excess unbound
antibodies were removed by two washes with PBS. Fol-
lowing these washes, the cells were resuspended in PBS
and analysed by flow cytometry using a FACSCalibur
flow cytometer (Becton Dickinson, BD Biosciences,
San Diego, USA). For determination of intracellular
CTLA-4 expression, the cells were first fixed for
10 min at room temperature in 2 % paraformaldehyde
(Fluka, Sigma-Aldrich, Buchs, Germany), washed in
PBS and incubated for 10 min at room temperature in
BD Permeabilizing Solution 2 (Becton Dickinson, BD
Biosciences, San Diego, USA) according to the manufac-
turer’s instructions. Then, the cells were incubated with
anti-CTLA-4 (CD152)/R-phycoerythrin (R-PE) mAbs for
30 min at 37 °C in the dark.
Ki67 protein was detected by staining of the cells with anti-
Ki67/fluorescein isothiocyanate (FITC) mAbs (BD
Pharmingen, BD Biosciences, San Diego, USA) after fixation
and permeabilisation as described in the case of intracellular
detection of the CTLA-4 molecule.
Negative controls were always done by omitting the mAbs
and by incubating the cells with mouse Ig of the same isotype
as the mAbs conjugated with RPE or FITC. At least 10,000
events per sample were analysed. The results were expressed
as the proportion of CTLA-4- or Ki67-positive cells. The
CellQuest program was used for statistical analysis of the
acquired data.
Apoptosis
Before and after cell culture, the apoptosis was determined





Number of patients 38
Gender (female/male) 15/23











Hb level (g/dl) 12.9±1.9
Platelet count (1×109/l) 135.2±55.1
LDH (U/l) 206.8±55.3
β2 microglobulin (mg/l) 3.3±1.4
For age and clinical parameters, the mean
values and standard deviation (SD) were
presented
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Kit, Fluorescein (Roche Diagnostics GmbH, Mannheim,
Germany) based on a terminal deoxynucleotidyl transferase
(TdT)-mediated dUTP nick-end labelling (TUNEL) assay.
At least 10,000 events per sample were analysed. The
CellQuest program was used for statistical analysis of the
acquired data.
Statistical analysis
Statistical analyses of the clinical data and laboratory
findings were conducted using Statistica 10.0 or PQStat
software. For clinical parameters, the mean values and
standard deviation were calculated. For all other analysed
variables, the median values and 25th and 75th interquar-
tile range were calculated.
All collected data were examined for normal distribu-
tion and for homogeneity of variances using the Shapiro-
Wilk test and Levene’s test, respectively. If data were
normally distributed and had homogeneous variances,
the comparisons between both studied groups of CLL pa-
tients and healthy individuals were performed using the
one-factor analysis of variance (ANOVA) followed by a
post hoc test (Scheffe F test). To test the effects of culture
and CTLA-4 blockade on analysed variables, the repeated
measures ANOVA and the Student’s t test for dependent
samples were used. If data were not normally distributed
and/or had heterogeneous variances, the non-parametric
Kruskal-Wallis one-way ANOVA by rank, the Friedman
ANOVA test followed by a post hoc test (Dunn test) and
the non-parametric Wilcoxon signed-rank test were ap-
plied. In all analyses, differences were considered signif-
icant when P≤0.05.
Results
Surface and intracellular expression of the CTLA-4
molecule in freshly drawn CLL cells and normal CD19+
lymphocytes
Since CTLA-4 is transiently expressed on the cell surface
and is predominantly located in intracellular compartments
due to constitutive internalisation from the plasma mem-
brane [27], we determined both surface (sCTLA-4) and
cytoplasmic (cCTLA-4) expression of this molecule. We
found significantly elevated expression of CTLA-4 in pa-
tients’ CLL cells compared to B cells from healthy con-
trols (p≤0.001; data not shown). Also worthy of note was
variability of both surface and cytoplasmic CTLA-4 ex-
pression in the CLL group, ranging from 3.5 to 57.1 %
and from 10.1 to 74.1 %, respectively. Based on the fact
that the surface CTLA-4 is of functional significance as a
regulator of cell activation, we divided the patients into
low and high expressors of the CTLA-4 molecule, taking
as a cut-off value the median percentage of sCTLA-4-
positive CLL cells (32.8 %). Accordingly, in the high
CTLA-4 expressors, the median proportions of both
sCTLA-4-positive cells and cCTLA-4-positive cells were
markedly higher compared to the low CTLA-4 expressors
and healthy individuals (Table 2). In contrast, no differ-
ences in the median frequencies of these cells between the
low CTLA-4 expressors and healthy volunteers were
found. Although the surface as well as cytoplasmic ex-
pression of the CTLA-4 molecule in single cells defined
as mean fluorescence intensity (MFI) was the highest in
the high CTLA-4 expressors and the lowest in the low
CTLA-4 expressors, the differences between all studied
groups were not statistically significant (data not shown).
Proliferation activity and apoptosis of freshly drawn
leukaemic cells from CLL patients with low and high
CTLA-4 expression and normal B lymphocytes
Since CTLA-4 is known as an anti-proliferative factor
[12, 13, 28], we examined whether freshly drawn CLL
cells from the two studied groups of CLL patients differ
regarding the proliferation activity; therefore, the expres-
sion of Ki67 protein in CLL cells was estimated. In both
studied groups of CLL patients, the proliferation activity
was low and comparable to that found in healthy individ-
uals (Table 3).
As CTLA-4 is involved in the regulation of cell survival
[21, 29], we also investigated whether freshly drawn CLL
cells from the two studied groups of CLL patients differ in
terms of the apoptosis rate. We did not detect any apoptotic
cells either in studied group of CLL patients or in healthy
individuals (Table 4).
Effect of ex vivo stimulation on expression of the CTLA-4
molecule in leukaemic cells from CLL patients with low
and high CTLA-4 expression, as well as normal CD19+
cells
Next, we investigated whether leukaemic cells from both
studied groups of CLL patients, in particular from the
low CTLA-4 expressors, are able to change CTLA-4 ex-
pression in response to ex vivo stimulation with DSP30
and rIL-2. As a control, cell culture in medium alone
was performed. In the low CTLA-4 expressors, no sig-
nificant impact of cell culture in medium alone or
ex vivo stimulation on the surface expression of the
CTLA-4 molecule was found, and the median propor-
tions of sCTLA-4+ CLL cells were comparable to those
observed in healthy individuals at each time point tested
(Table 2, Figs. 1 and 2). In contrast, in the high CTLA-4
expressors, both control and stimulating culture led to a
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gradual decrease in the median percentages of sCTLA-4-
positive leukaemic cells, with the minimum value after
72 h (Table 2, Figs. 1 and 2). In consequence, after 72 h
of culture in medium alone as well as after 24 and 72 h
of stimulating culture, the median frequencies of sCTLA-
4-positive cells in the high CTLA-4 expressors became
comparable to those observed in the low CTLA-4
expressors and healthy individuals (Table 2). In healthy
volunteers, cell culture in medium alone led to a gradual
decrease in the median proportion of CD19+sCTLA-4+
cells, with the minimum value after 72 h (Figs. 1 and
2). Of note, after 72 h of ex vivo stimulation, the median
frequency of sCTLA-4-positive CD19+ lymphocytes was
markedly higher than in the cell culture in medium alone
(Figs. 1 and 2).
As regard cytoplasmic expression of the CTLA-4 mole-
cule, in both studied groups of CLL patients, no significant
impact of control or stimulating culture on the expression of
CTLA-4 was observed (Table 2, Figs. 1 and 3). Moreover, no
significant differences between the studied groups of CLL
patients after cell culture were found (Table 2). It is notewor-
thy that in the high CTLA-4 expressors, the median percent-
ages of cCTLA-4-positive leukaemic cells remainedmarkedly
higher than in healthy volunteers at each time point tested
(Table 2), whereas in the low CTLA-4 expressors, the median
proportion of cCTLA-4+ leukaemic cells became markedly
higher than in healthy individuals only after 72 h of ex vivo
stimulation (Table 2).
In healthy controls, after 72 h of cell culture in medium
alone, we observed a marked decrease in the median
Table 2 Median proportions and 25th–75th interquartile range of leukaemic cells and normal B cells co-expressing CTLA-4 molecule
Groups Unstimulated 24-h culture 72-h culture
Medium alone DSP30+rIL-2 Medium alone DSP30+rIL-2
% sCTLA-4-positive cells
Low CTLA-4 expressors (n=19) 22.9 [19.2–26.9] 24.5 [16.3–33.8] 22.9 [18.4–28.5] 16.9 [12.5–25.0] 14.9 [10.7–28.0]
High CTLA-4 expressors (n=19) 44.6 [35.4–53.3] 32.0 [27.6–40.7] 26.7 [25.3–29.4] 18.7 [16.6–25.0] 18.9 [17.0–23.2]
Controls (n=15) 18.8 [17.9–20.1] 17.9 [11.4–24.9] 20.9 [13.2–28.5] 11.8 [6.0–14.9] 14.8 [11.1–24.5]
Low vs high CTLA-4 expressors P=0.0000001 P=0.03 NS NS NS
Low CTLA-4 expressors vs controls NS NS NS NS NS
High CTLA-4 expressors vs controls P=0.0000001 P=0.009 NS NS NS
% cCTLA-4-positive cells
Low CTLA-4 expressors (n=19) 29.7 [19.6–39.7] 45.0 [30.1–58.2] 45.3 [36.7–55.1] 29.0 [13.4–43.2] 36.4 [23.6–63.4]
High CTLA-4 expressors (n=19) 54.4 [43.8–65.5] 53.2 [49.6–60.0] 56.9 [51.4–67.6] 46.2 [37.5–53.2] 50.1 [44.1–57.0]
Controls (n=15) 25.7 [8.7–33.1] 30.4 [23.0–37.3] 26.2 [21.3–40.7] 14.1 [9.6–21.3] 19.1 [4.5–27.0]
Low vs high CTLA-4 expressors P=0.005 NS NS NS NS
Low CTLA-4 expressors vs controls NS NS NS NS P=0.004
High CTLA-4 expressors vs controls P=0.00004 P=0.002 P=0.0004 P=0.0007 P=0.000005
Table 3 Median proportions and 25th–75th interquartile range of leukaemic cells and normal B cells co-expressing Ki67
Groups Unstimulated 24-h culture 72-h culture
Medium alone DSP30+rIL-2 Medium alone DSP30+rIL-2
% Ki67-positive cells
Low CTLA-4 expressors (n=19) 2.1 [0.3–4.5] 2.2 [1.3–4.3] 10.6 [3.8–28.8] 1.5 [1.1–1.9] 9.2 [4.0–21.6]
High CTLA-4 expressors (n=19) 3.3 [1.6–3.6] 2.3 [1.3–3.6] 10.2 [2.5–15.1] 2.2 [1.6–3.0] 9.3 [5.9–12.0]
Controls (n=15) 1.0 [0.0–2.8] 0.0 [0.0–0.2] 13.2 [10.2–15.0] 0.4 [0.0–3.3] 13.4 [11.3–17.5]
Low vs high CTLA-4 expressors NS NS NS NS NS
Low CTLA-4 expressors vs controls NS NS NS NS NS
High CTLA-4 expressors vs controls NS NS NS NS P=0.05
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percentage of CD19+cCTLA-4+ cells (Table 2, Figs. 1 and 3).
Moreover, after 72 h of ex vivo stimulation, the median pro-
portion of cCTLA-4-positive CD19+ lymphocytes was signif-
icantly higher than in the cell culture in medium alone (Figs. 1
and 3).
Effect of ex vivo stimulation on the proliferation capacity
of leukaemic cells from CLL patients with low and high
CTLA-4 expression and normal B lymphocytes
Next, we asked whether the two studied groups of CLL pa-
tients differ in terms of proliferation activity following ex vivo
stimulation. To answer this question, the expression of Ki67
protein in leukaemic cells after the cell culture in medium
alone and in the presence of DSP30+ IL-2 was examined. In
both studied groups of CLL patients as well as in healthy
individuals, no significant impact of the culture in medium
alone on the median proportions of Ki67-positive cells was
found (Fig. 4); moreover, the proliferation activity was com-
parable in both groups of CLL patients and healthy volunteers
(Table 3). In contrast, ex vivo stimulation led to a marked
increase in the median frequencies of Ki67+ cells in all studied
groups (Fig. 4). Although the median percentages of Ki67-
positive cells did not significantly differ between the studied
Table 4 Median proportions and
25th–75th interquartile range of
apoptotic leukaemic cells and
normal B cells
Groups Before cell culture 72-h culture
Medium alone DSP30+rIL-2
% Apoptotic cells
Low CTLA-4 expressors (n=19) 0.0 [0.0–0.0] 34.3 [24.9–40.5] 44.4 [33.6–58.4]
High CTLA-4 expressors (n=19) 0.0 [0.0–0.0] 19.2 [13.8–24.6] 51.4 [29.6–64.0]
Controls (n=15) 0.0 [0.0–0.0] 26.2 [22.4–28.7] 49.3 [39.9–67.1]
Low vs high CTLA-4 expressors NS P=0.02 NS
Low CTLA-4 expressors vs controls NS NS NS
High CTLA-4 expressors vs controls NS NS NS
Fig. 1 Surface (s) and intracellular expression (c) of CTLA-4 in studied groups of CLL patients and healthy donors before and after cell culture. Boxes
and whiskers: 25th–75th interquartile range and min.-max., respectively; the median is the central line in each box
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groups of CLL patients at each time point tested (Table 3), and
in the low CTLA-4 expressors the median proportions of
Ki67+ leukaemic cells following ex vivo stimulation were
comparable to the corresponding cells in healthy individuals,
we observed that in the high CTLA-4 expressors, the median
frequency of Ki67-positive leukaemic cells after 72 h of stim-
ulating culture was markedly lower than in healthy controls
(Table 3).
Fig. 2 Representative examples
of flow cytometric analyses of the
surface expression of CTLA-4
(sCTLA-4) in studied groups of
CLL patients and healthy
controls. Grey histograms
represent isotype controls.
Numbers on histograms represent
the percentage of the cells
expressing CTLA-4 on the cell
surface
Tumor Biol. (2016) 37:4143–4157 4149
Effect of ex vivo stimulation on the rate of apoptosis
of leukaemic cells from CLL patients with low and high
CTLA-4 expression and normal B lymphocytes
Simultaneously with proliferation activity, we assessed the
apoptosis rate of the studied cells under non-stimulating and
stimulating conditions. In both groups of CLL patients as well
as in healthy volunteers, we observed a marked increase in the
median frequencies of apoptotic cells after culture in medium
alone (Table 4, Fig. 5). Of note, the highest increase in the
apoptotic cell frequencies was seen in the low CTLA-4
expressors, whereas the smallest increase was found in the
Fig. 3 Representative examples
of flow cytometric analyses of
intracellular expression of CTLA-
4 (cCTLA-4) in studied groups of
CLL patients and healthy
controls. Grey histograms
represent isotype controls.
Numbers on histograms represent
the percentage of the cCTLA-4-
positive cells
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high CTLA-4 expressors (Table 4, Fig. 5). In consequence, the
median proportion of apoptotic cells after 72 h of culture in
medium alone in the low CTLA-4 expressors was significant-
ly higher compared with the high CTLA-4 expressors
(Table 4). Ex vivo stimulation led to a further increase in the
median frequencies of apoptotic cells to comparable levels in
all studied groups (Table 4, Figs. 5 and 6).
Effect of CTLA-4 blockade on proliferation activity
of leukaemic cells from CLL patients with low and high
CTLA-4 expression and normal B lymphocytes
To find out whether CTLA-4 blockade on the cell surface
would affect the proliferation activity, we estimated the medi-
an proportions of Ki67-positive cells after cell culture in the
Fig. 4 Ki67 expression in studied groups of CLL patients and healthy donors before and after cell culture. Boxes and whiskers: 25th–75th interquartile
range and min.-max., respectively; the median is the central line in each box
Fig. 5 Apoptosis in studied
groups of CLL patients and
healthy donors before and after
cell culture. Boxes and whiskers:
25th–75th interquartile range and
min.-max., respectively; the
median is the central line in each
box
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presence of DSP30, rIL-2 and the blocking anti-CTLA-4mAb
in all studied groups. In the low CTLA-4 expressors as well as
in healthy individuals, no significant impact of CTLA-4
blockade on the median percentages of Ki67+ cells was ob-
served (Figs. 7 and 8). In contrast, in the high CTLA-4
expressors, CTLA-4 blockade led to a marked increase in
proliferation activity after 24 and 72 h of culture (Figs. 7 and
8), and the median proportion of Ki67-positive cells after 72 h
of blocking culture in this group of CLL patients was signif-
icantly higher than in healthy individuals (P=0.03).
Effect of CTLA-4 blockade on apoptosis of leukaemic cells
from CLL patients with low and high CTLA-4 expression
and normal B lymphocytes
Simultaneously with proliferation activity, we decided to ex-
plain whether blocking CTLA-4 on the CLL cell surface
would affect apoptosis. In the blocking culture, we observed
a further increase in the median frequencies of apoptotic cells
in the low CTLA-4 expressors and, more importantly, in
healthy individuals, although this increase was not statistically
significant (Figs. 5 and 6). In contrast, in the high CTLA-4
expressors, a tendency to decrease in the median proportion of
apoptotic cells after CTLA-4 blockade was observed (Figs. 5
and 6). In consequence, in the high CTLA-4 expressors, the
median percentage of apoptotic cells after CTLA-4 blockade
was markedly lower than in healthy volunteers (P=0.03),
whereas in the low CTLA-4 expressors, the median propor-
tion of apoptotic cells was comparable to the value found in
healthy individuals.
Discussion
Herein, we report that CLL leukemic cells exhibit high
variability in the response to in vitro stimulation and
Fig. 6 Representative examples
of flow cytometric analyses of
apoptosis in studied groups of
CLL patients and healthy
controls. Grey histograms
represent isotype controls.
Numbers on histograms represent
the percentage of the apoptotic
cells
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CTLA-4 blockade depending on the pattern of surface
CTLA-4 expression. Considering the fact that both CLL
cells and T cells, including the Treg microenvironment,
can be targeted by CTLA-4 blocking antibody in a pos-
sible immunotherapy approach, our current findings may
be of potential clinical relevance.
To the best of our knowledge, among the available reports
concerning expression of the CTLA-4 molecule in CLL pa-
tients [16–21, 30, 31], only four of them concerned CTLA-4
expression and its function in peripheral blood leukaemic B
cells [18–21]. Of note, literature data regarding CTLA-4 ex-
pression in CLL cells following ex vivo stimulation with CpG
oligodeoxynucleotides (ODNs) are lacking so far. The inter-
esting finding of the present study was that only in the high
CTLA-4 expressors were the median percentages of freshly
isolated leukaemic cells co-expressing CTLA-4 on the surface
as well as in intracellular compartments significantly higher
than in healthy individuals. In the low CTLA-4 expressors, the
median proportions of both sCTLA-4-positive cells and
cCTLA-4-positive cells were comparable to those found in
healthy individuals, and a tendency to lower expression of
the CTLA-4 molecule in single cells was observed. This find-
ing raises the question about the mechanisms underlying the
varied levels of CTLA-4 expression in malignant B cells in
CLL patients. Based on our previous notion thatCTLA-4 gene
polymorphisms may influence CTLA-4 expression level in
CLL cells [20, 22], it is possible that the high level of
CTLA-4 expression in some of the CLL patients might result
from the presence of specific alleles predisposing to upregu-
lation of expression of the CTLA-4 molecule. The other pos-
sible explanation is a potential negative feedback loop be-
tween CTLA-4 and NFAT1 (nuclear factor of activated T
cells; also known as NFATc2) [21]. NFAT1 binds to the pro-
moter of theCTLA-4 gene and controls its expression [32–34].
The most recent study showed significantly lower expression
of NFAT1 in the high CTLA-4 expressors compared to the
low CTLA-4 expressors [21]. Moreover, we cannot exclude
that in some CLL patients, signals coming from tissue com-
partments, including the bone marrow and secondary lym-
phoid organs, suppress the expression of the CTLA-4 mole-
cule. Recently, Mittal et al. [21] showed that in peripheral
blood CLL cells co-cultured on endothelial-derived stromal
cells and bone marrow-derived stromal cells, expression of
the CTLA-4 gene was down-regulated.
An original finding of this study was that CLL patients also
differ regarding the pattern of CTLA-4 expression following
cell culture. In the low CTLA-4 expressors, the surface as well
as cytoplasmic expression of CTLA-4 remained unchanged
under both non-stimulating (cell culture in medium alone)
and stimulating conditions (DSP30+rIL-2). In contrast, in
the high CTLA-4 expressors, a gradual decrease of surface
CTLA-4 expression on leukaemic cells during culture in me-
dium alone was observed. Moreover, in the same group,
ex vivo stimulation led to a further significant decrease in
the surface expression of the CTLA-4 molecule. Simulta-
neously, the median proportions of cytoplasmic CTLA-4-
positive cells did not change during the cell culture in medium
alone or in the presence of DSP30 and rIL-2. These observa-
tions seem to suggest that the down-regulation of surface ex-
pression of CTLA-4 observed in the high CTLA-4-expressing
CLL patients may result from disturbed recycling of the
CTLA-4 molecule to the cell surface. Furthermore, the differ-
ence in expression of CTLA-4 between the studied groups of
CLL patients upon ex vivo stimulation seems to confirm the
observations of other authors that the response of leukaemic
cells to CpG ODN stimulation is heterogeneous [35–37]. The
reason for the different patterns of CTLA-4 molecule expres-
sion in response to ex vivo DSP30+rIL-2 stimulation in the
studied groups of CLL patients requires further clarification.
On the other hand, as the high level of CTLA-4 expression in
Fig. 7 Ki67 expression in studied groups of CLL patients and healthy donors after blocking culture. Boxes and whiskers: 25th–75th interquartile range
and min.-max., respectively; the median is the central line in each box
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CLL cells is one of the good prognostic factors [19], applica-
tion of CpG ODN that reduces the surface expression of
CTLA-4 in leukaemic cells as a therapeutic agent seems to
be an unfavourable strategy for CLL patients.
Since CTLA-4 is involved in regulation of proliferation
[12, 13, 28] and cell survival [29], an intriguing question is
whether the peripheral blood leukaemia cells from CLL pa-
tients differ in terms of the proliferation activity and apoptosis
before as well as after ex vivo stimulation regarding CTLA-4
expression. Analysis of the expression of Ki67 protein in
freshly drawn lymphocytes as well as in cells cultured with
DSP30 and rIL-2 showed no significant differences in prolif-
eration activity of leukaemic cells from the two studied groups
of CLL patients at each time point tested. With regard to
freshly isolated CLL cells, we suggest that this lack of a
marked difference in the median proportions of Ki67-
positive cells between studied groups of CLL patients may
result from the relatively low proliferation activity of the pe-
ripheral blood leukaemic lymphocytes in vivo. In fact, the vast
majority of circulating CLL cells are arrested in the G0/G1
phase of the cell cycle [20, 38] and do not express Ki67 pro-
tein [39]. As regard proliferation activity after ex vivo stimu-
lation, we assume that the observed lack of significant differ-
ences between studied groups of CLL patients may be caused
by a gradual decline of CTLA-4 expression in the high CTLA-
4 expressors following ex vivo stimulation to the level found
in the low CTLA-4 expressors.
An interesting finding of the present study was that the
studied groups of CLL patients also differ in terms of apopto-
sis following cell culture.We found that after 72 h of culture in
Fig. 8 Effect of CTLA-4 block-
ade on Ki67 expression in studied
groups of CLL patients and
healthy controls. a
Histograms show representative
data of flow cytometric analyses
of the expression of Ki67 protein
after 24 h of blocking culture. b
Histograms show representative
data illustrating expression of
Ki67 protein after 72 h of
blocking culture. Grey histograms
represent isotype controls.
Numbers on histograms represent
the percentage of cells expressing
Ki67
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medium alone, a lower proportion of CLL cells from the high
CTLA-4 expressors became apoptotic compared to those from
the low CTLA-4 expressors, which corresponded with the
significant down-regulation of surface CTLA-4 expression
only in the high CTLA-4 expressors. Accordingly, Mittal
et al. [21] connected the down-regulation of CTLA-4 expres-
sion in CLL cells with the declined apoptosis of these cells.
The authors reported that the decline of CTLA-4 expression in
CLL cells led to decreased frequency of apoptotic cells as a
result of increased expression of the anti-apoptotic molecule B
cell lymphoma 2 (Bcl-2) observed at both the mRNA and
protein levels.
One of the main aims of the present study was to investi-
gate the effect of CTLA-4 blockade on the proliferation activ-
ity and apoptosis of CLL cells. As clinical trials with systemic
administration of ipilimumab (fully human mAb directed
against CTLA-4, formerly MDX-010) in CLL were recently
performed [23], the results of these experiments not only
broaden our knowledge about the role of the CTLA-4 mole-
cule in the regulation of proliferation and survival of CLL
cells, but also provide very important information from the
clinical point of view. In the current study, we observed a
significant increase in the median proportion of Ki67-
positive leukaemic cells following CTLA-4 blockade, but on-
ly in the high CTLA-4 expressors. It is noteworthy that in the
high CTLA-4 expressors, proliferation activity of leukaemic
cells might be a result of two signals: one originating from the
down-regulation of CTLA-4 expression following CpG ODN
stimulation observed in this group only and the second one
coming from blockage of the CTLA-4-mediated inhibitory
signal. The relationship of CTLA-4 down-regulation in CLL
cells with the increased proliferation of these cells measured
by MTT and 3H-thymidine uptake assays as well as by Ki67
protein expression was recently observed [21]. Furthermore,
in CLL cells with rapidly down-regulated expression of
CTLA-4, a significant increase in the expression level of the
transcription factor signal transducer and activator of tran-
scription 1 (STAT1) as well as in its phosphorylation level
was observed [21]. STAT1 is phosphorylated by the phosphor-
ylated form of p38 mitogen-activated protein kinase
(p38MAPK), which is a downstream effector of BCR
crosslinking as well as TLR9 engagement by its ligands,
CpG-ODNs [40, 41]. Recently, Comin-Anduix et al. [42] re-
ported that PBMCs from patients with metastatic melanoma
treated with tremelimumab (fully human IgG2 mAb against
CTLA-4 in clinical development for patients with cancer)
were characterised by an increased level of phosphorylated
form of p38MAPK (pp38MAPK). Thus, as down-regulation
of CTLA-4 expression results in the increase and phosphory-
lation of STAT1 in CLL cells [21] and CTLA-4 blockade may
lead to an increased level of pp38MAPK [42], we cannot
exclude that the increased proliferation activity in the high
CTLA-4 expressors following CTLA-4 blockade might result
from activation of STAT pathways. On the other hand, it still
remains unsolved why, in the low CTLA-4 expressors,
CTLA-4 blockade did not affect the proliferation activity of
leukaemic cells; probably, the optimal level of CTLA-4 ex-
pression is needed.
Similarly, we observed the impact of CTLA-4 blockade on
apoptosis of CLL cells. However, we found an opposite influ-
ence of CTLA-4 blockade on the frequency of apoptotic cells
in studied groups of CLL patients regarding CTLA-4 expres-
sion. Among the patients, a high tendency to decrease in ap-
optotic cell frequency following CTLA-4 blockade was noted
in the high CTLA-4 expressors. Consequently, we observed a
markedly lower apoptosis rate in these patients compared to
controls. In the low CTLA-4 expressors as well as in healthy
individuals, a tendency to an increase in the median percent-
ages of apoptotic cells was observed. Based on the mentioned
study [21], we strongly suggest that quick down-regulation of
CTLA-4 expression after blockade may result in increased
expression of anti-apoptotic Bcl-2. On the other hand, block-
ade of CTLA-4 may result in inactivation of the phos-
phatidylinositol 3-kinase/protein kinase B (PI3K/Akt) path-
way. It has been shown that CTLA-4 induces activation of
the PI3K/Akt pathway, resulting in inactivation of the pro-
apoptotic factor Bcl-2 antagonist of cell death (BAD) and
upregulation of the survival factor B cell lymphoma-extra
large (Bcl-XL) [29]. Thus, inactivation of the PI3K/Akt path-
way following CTLA-4 blockade may block the inactivation
of BAD and promote, in consequence, the apoptosis of cells.
In the light of our findings, we can suppose that in the high
CTLA-4 expressors, the pro-survival signal originating from
the rapid down-regulation of CTLA-4 expression seems to
prevail. Conversely, in the low CTLA-4 expressors and
healthy individuals, where down-regulation of CTLA-4 ex-
pression was not observed, predominance of the pro-
apoptotic signal resulting from inactivation of the PI3K/Akt
pathway upon CTLA-4 blockade should not be excluded. Ad-
ditional studies are needed to explain the mechanisms leading
to a decrease or increase in the frequency of apoptosis of
leukaemic cells following CTLA-4 blockade.
In summary, we have demonstrated for the first time the
different pattern of ex vivo-stimulated CTLA-4 expression in
low and high CTLA-4-expressing CLL groups. Furthermore,
the rate of CTLA-4 expression seems to determine prolifera-
tion activity and apoptosis of CLL cells; CTLA-4 blockade in
high CTLA-4 expressors induces pro-survival signals in CLL
cells, indicating that the systemic administration of a CTLA-4
blocking antibody as immunotherapy might be an
unfavourable strategy for these patients. In contrast, this form
of immunotherapy might benefit CLL patients with low
CTLA-4 expression on leukaemic cells (which predicts a poor
clinical outcome), since CTLA-4 blockade does not affect
proliferation and apoptosis of malignant B cells in this group.
Therefore, CTLA-4 expression on B cells might distinguish
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CLL patients in whom systemic administration of a CTLA-4
blocking antibody for T cell effector function improvement is
beneficial and safe.
Acknowledgments This work was supported by a grant from the Na-
tional Science Centre (Poland, project number: N N402 284936).
Compliance with ethical standards
Conflicts of interest None
Open Access This article is distributed under the terms of the Creative
Commons Attr ibution 4.0 International License (http: / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted
use, distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a link
to the Creative Commons license, and indicate if changes were made.
References
1. Hallek M, Pflug N. Chronic lymphocytic leukemia. Ann Oncol.
2010;21 Suppl 7:vii154–64. doi:10.1093/annonc/mdq373.
2. Hallek M. Chronic lymphocytic leukemia: 2015 update on diagno-
sis, risk stratification, and treatment. Am J Hematol. 2015;90(5):
446–60. doi:10.1002/ajh.23979.
3. Herishanu Y, Polliack A. Chronic lymphocytic leukemia: a review
of some new aspects of the biology, factors influencing prognosis
and therapeutic options. Transfus Apher Sci. 2005;32(1):85–97.
doi:10.1016/j.transci.2004.10.012.
4. Abbott BL. Chronic lymphocytic leukemia: recent advances in di-
agnosis and treatment. Oncologist. 2006;11(1):21–30. doi:10.1634/
theoncologist.11-1-21.
5. Caligaris-Cappio F, Bertilaccio MT, Scielzo C. How the microen-
vironment wires the natural history of chronic lymphocytic leuke-
mia. Semin Cancer Biol. 2014;24:43–8. doi:10.1016/j.semcancer.
2013.06.010.
6. Hamilton E, Pearce L, Morgan L, et al. Mimicking the tumour
microenvironment: three different co-culture systems induce a sim-
ilar phenotype but distinct proliferative signals in primary chronic
lymphocytic leukaemia cells. Br J Haematol. 2012;158(5):589–99.
doi:10.1111/j.1365-2141.2012.09191.x.
7. Herishanu Y, Perez-Galan P, Liu D, et al. The lymph node micro-
environment promotes B-cell receptor signaling, NF-kappaB acti-
vation, and tumor proliferation in chronic lymphocytic leukemia.
Blood. 2011;117(2):563–74. doi:10.1182/blood-2010-05-284984.
8. Messmer BT, Messmer D, Allen SL, et al. In vivo measurements
document the dynamic cellular kinetics of chronic lymphocytic
leukemia B cells. J Clin Invest. 2005;115(3):755–64. doi:10.1172/
JCI23409.
9. Karp M, Giannopoulos K. Antigen stimulation in the development
of chronic lymphocytic leukemia. Postepy Hig Med Dosw
(Online). 2013;67:1204–13. doi:10.5604/17322693.1078852.
10. Zenz T, Dohner H, Stilgenbauer S. Genetics and risk-stratified ap-
proach to therapy in chronic lymphocytic leukemia. Best Pract Res
Clin Haematol. 2007;20(3):439–53. doi:10.1016/j.beha.2007.02.
006.
11. Hamblin TJ, Oscier DG. Chronic lymphocytic leukaemia: the na-
ture of the leukaemic cell. Blood Rev. 1997;11(3):119–28.
12. Walunas TL, LenschowDJ, Bakker CY, et al. CTLA-4 can function
as a negative regulator of T cell activation. Immunity. 1994;1(5):
405–13.
13. Walunas TL, Bakker CY, Bluestone JA. CTLA-4 ligation blocks
CD28-dependent T cell activation. J Exp Med. 1996;183(6):2541–
50.
14. Kosmaczewska A, Ciszak L, Potoczek S, Frydecka I. The signifi-
cance of Treg cells in defective tumor immunity. Arch Immunol
Ther Exp. 2008;56(3):181–91. doi:10.1007/s00005-008-0018-1.
15. Beyer M, Kochanek M, Darabi K, et al. Reduced frequencies and
suppressive function of CD4+ CD25hi regulatory Tcells in patients
with chronic lymphocytic leukemia after therapy with fludarabine.
Blood. 2005;106(6):2018–25. doi:10.1182/blood-2005-02-0642.
16. Frydecka I, Kosmaczewska A, Bocko D, et al. Alterations of the
expression of T-cell-related costimulatory CD28 and
downregulatory CD152 (CTLA-4) molecules in patients with B-
cell chronic lymphocytic leukaemia. Br J Cancer. 2004;90(10):
2042–8. doi:10.1038/sj.bjc.6601833.
17. Motta M, Rassenti L, Shelvin BJ, et al. Increased expression of
CD152 (CTLA-4) by normal T lymphocytes in untreated patients
with B-cell chronic lymphocytic leukemia. Leukemia. 2005;19(10):
1788–93. doi:10.1038/sj.leu.2403907.
18. Ciszak L, Frydecka I, Wolowiec D, Szteblich A, Kosmaczewska A.
CTLA-4 affects expression of key cell cycle regulators of G0/G1
phase in neoplastic lymphocytes from patients with chronic lym-
phocytic leukaemia. Clin Exp Med. 2015. doi:10.1007/s10238-
015-0360-7.
19. Joshi AD, Hegde GV, Dickinson JD, et al. ATM, CTLA4, MNDA,
and HEM1 in high versus low CD38 expressing B-cell chronic
lymphocytic leukemia. Clin Cancer Res. 2007;13(18 Pt 1):5295–
304. doi:10.1158/1078-0432.CCR-07-0283.
20. KosmaczewskaA, Ciszak L, Suwalska K,Wolowiec D, Frydecka I.
CTLA-4 overexpression in CD19+/CD5+ cells correlates with the
level of cell cycle regulators and disease progression in B-CLL
patients. Leukemia. 2005;19(2):301–4. doi:10.1038/sj.leu.
2403588.
21. Mittal AK, Chaturvedi NK, Rohlfsen RA, et al. Role of CTLA4 in
the proliferation and survival of chronic lymphocytic leukemia.
PLoS One. 2013;8(8):e70352. doi:10.1371/journal.pone.0070352.
22. Suwalska K, Pawlak E, Karabon L, et al. Association studies of
CTLA-4, CD28, and ICOS gene polymorphisms with B-cell chron-
ic lymphocytic leukemia in the Polish population. Hum Immunol.
2008;69(3):193–201. doi:10.1016/j.humimm.2008.01.014.
23. Bashey A, Medina B, Corringham S, et al. CTLA4 blockade with
ipilimumab to treat relapse of malignancy after allogeneic hemato-
poietic cell transplantation. Blood. 2009;113(7):1581–8. doi:10.
1182/blood-2008-07-168468.
24. LiangH,Nishioka Y, Reich CF, PisetskyDS, Lipsky PE. Activation
of human B cells by phosphorothioate oligodeoxynucleotides. J
Clin Invest. 1996;98(5):1119–29. doi:10.1172/JCI118894.
25. Decker T, Schneller F, Kronschnabl M, et al. Immunostimulatory
CpG-oligonucleotides induce functional high affinity IL-2 receptors
on B-CLL cells: costimulation with IL-2 results in a highly immu-
nogenic phenotype. Exp Hematol. 2000;28(5):558–68.
26. Alegre ML, Shiels H, Thompson CB, Gajewski TF. Expression and
function of CTLA-4 in Th1 and Th2 cells. J Immunol. 1998;161(7):
3347–56.
27. Linsley PS, Bradshaw J, Greene J, Peach R, Bennett KL, Mittler
RS. Intracellular trafficking of CTLA-4 and focal localization to-
wards sites of TCR engagement. Immunity. 1996;4(6):535–43.
28. Lee KM, Chuang E, Griffin M, et al. Molecular basis of T cell
inactivation by CTLA-4. Science. 1998;282(5397):2263–6.
29. Schneider H, Valk E, Leung R, Rudd CE. CTLA-4 activation of
phosphatidylinositol 3-kinase (PI 3-K) and protein kinase B (PKB/
AKT) sustains T-cell anergy without cell death. PLoS One.
2008;3(12):e3842. doi:10.1371/journal.pone.0003842.
4156 Tumor Biol. (2016) 37:4143–4157
30. Scrivener S, Kaminski ER, Demaine A, Prentice AG. Analysis of
the expression of critical activation/interaction markers on peripher-
al blood T cells in B-cell chronic lymphocytic leukaemia: evidence
of immune dysregulation. Br J Haematol. 2001;112(4):959–64.
31. Scrivener S, Goddard RV, Kaminski ER, Prentice AG. Abnormal T-
cell function in B-cell chronic lymphocytic leukaemia. Leuk
Lymphoma. 2003;44(3):383–9. doi:10.1080/1042819021000029993.
32. Chan DV, Gibson HM, Aufiero BM, et al. Differential CTLA-4
expression in human CD4+ versus CD8+ T cells is associated with
increased NFAT1 and inhibition of CD4+ proliferation. Genes
Immun. 2014;15(1):25–32. doi:10.1038/gene.2013.57.
33. Gibson HM, Hedgcock CJ, Aufiero BM, et al. Induction of the
CTLA-4 gene in human lymphocytes is dependent on NFAT bind-
ing the proximal promoter. J Immunol. 2007;179(6):3831–40.
34. Wu Y, Borde M, Heissmeyer V, et al. FOXP3 controls regulatory T
cell function through cooperation with NFAT. Cell. 2006;126(2):
375–87. doi:10.1016/j.cell.2006.05.042.
35. Chatzouli M, Ntoufa S, Papakonstantinou N, et al. Heterogeneous
functional effects of concomitant B cell receptor and TLR stimula-
tion in chronic lymphocytic leukemia with mutated versus
unmutated Ig genes. J Immunol. 2014;192(10):4518–24. doi:10.
4049/jimmunol.1302102.
36. Jahrsdorfer B, Wooldridge JE, Blackwell SE, et al .
Immunostimulatory oligodeoxynucleotides induce apoptosis of B
cell chronic lymphocytic leukemia cells. J Leukoc Biol.
2005;77(3):378–87. doi:10.1189/jlb.0604373.
37. Longo PG, Laurenti L, Gobessi S, et al. The Akt signaling pathway
determines the different proliferative capacity of chronic lympho-
cytic leukemia B-cells from patients with progressive and stable
disease. Leukemia. 2007;21(1):110–20. doi:10.1038/sj.leu.
2404417.
38. Andreeff M, Darzynkiewicz Z, Sharpless TK, Clarkson BD,
Melamed MR. Discrimination of human leukemia subtypes by
flow cytometric analysis of cellular DNA and RNA. Blood.
1980;55(2):282–93.
39. Granziero L, Ghia P, Circosta P, et al. Survivin is expressed on
CD40 stimulation and interfaces proliferation and apoptosis in B-
cell chronic lymphocytic leukemia. Blood. 2001;97(9):2777–83.
40. Kumagai Y, Takeuchi O, Akira S. TLR9 as a key receptor for the
recognition of DNA. Adv Drug Deliv Rev. 2008;60(7):795–804.
doi:10.1016/j.addr.2007.12.004.
41. Pone EJ, Xu Z, White CA, Zan H, Casali P. B cell TLRs and
induction of immunoglobulin class-switch DNA recombination.
Front Biosci (Landmark Ed). 2012;17:2594–615.
42. Comin-Anduix B, Sazegar H, Chodon T, et al. Modulation
of cell signaling networks after CTLA4 blockade in patients
with metastatic melanoma. PLoS One. 2010;5(9):e12711.
doi:10.1371/journal.pone.0012711.
Tumor Biol. (2016) 37:4143–4157 4157
